Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP3 | P05413 | 2/20 | 0.55 |
| ▸ | FABP4 | P15090 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | TYK2 | P29597 | 1/20 | 0.51 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.49 |
| ▸ | DPP4 | P27487 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.46 |
| ▸ | FEN1 | P39748 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | RORC | P51449 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30676249 | 1.00 | FABP3 (0.55) | FABP3FABP4ALDH1A1TDP1L3MBTL1 | |
| SCHEMBL1514599 | 0.90 | FABP3 (0.51) | FABP3FABP4ALDH1A1TDP1L3MBTL1 | |
| SCHEMBL19359128 | 0.86 | ALDH1A1 (0.47) | FABP3FABP4ALDH1A1TDP1L3MBTL1 | |
| SCHEMBL80183 | 0.84 | ALDH1A1 (0.64) | FABP3FABP4ALDH1A1DPP4KMT2A | |
| SCHEMBL355272 | 0.84 | TDP1 (0.61) | FABP3FABP4ALDH1A1TDP1L3MBTL1 | |
| SCHEMBL13100052 | 0.83 | ALDH1A1 (0.52) | FABP3FABP4ALDH1A1TYK2TRPM4 | |
| SCHEMBL476833 | 0.83 | ALDH1A1 (0.71) | FABP3FABP4ALDH1A1TDP1L3MBTL1 | |
| SCHEMBL11466346 | 0.81 | TDP1 (0.59) | FABP3FABP4ALDH1A1TDP1L3MBTL1 | |
| SCHEMBL6907913 | 0.81 | TDP1 (0.59) | FABP3FABP4ALDH1A1TDP1L3MBTL1 | |
| SCHEMBL6916441 | 0.81 | TDP1 (0.59) | FABP3FABP4ALDH1A1TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 676 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113683499-B | Method for preparing Du Weili siberian intermediate | 上海皓鸿生物医药科技有限公司 | 2024-01-30 | — | — | CN | claimed |
| CN-113683499-A | Method for preparing Duvirucisib intermediate | 上海皓鸿生物医药科技有限公司 | 2021-11-23 | — | — | CN | claimed |
| CN-106588604-A | Method for preparing chlorobenzaldehyde through continuous oxidization of m-chlorobenzene | 常州大学 | 2017-04-26 | — | — | CN | claimed |
| JP-4643102-B2 | — | — | 2011-03-02 | — | — | JP | claimed |
| EP-1240130-B1 | METHOD FOR OXIDATION OF XYLENE DERIVATIVES | SABIC INNOVATIVE PLASTICS IP (NL) | 2009-05-06 | — | — | EP | claimed |
| EP-1235782-B1 | METHOD FOR OXIDATION OF XYLENE DERIVATIVES | GEN ELECTRIC (US) | 2004-02-18 | — | — | EP | claimed |
| US-6469205-B1 | PRODUCING 4-CHLOROPHTHALIC ANHYDRIDE BY OXIDIZING A SUBSTRATE COMPRISING 4-CHLORO-ORTHO-XYLENE | GENERAL ELECTRIC COMPANY | 2002-10-22 | — | — | US | claimed |
| US-6465685-B1 | SUCH AS CHLORO-O-XYLENE, ARE OXIDIZED IN A SOLVENT IN THE PRESENCE OF A METAL COMPOUND CATALYST WITH ADDITION OF PROMOTER AFTER THE REACTION HAS PROCEEDED TO AN INTERMEDIATE STAGE; PRODUCT COMPRISES CHLOROPHTHALIC ACID OR ANHYDRIDE | GENERAL ELECTRIC COMPANY | 2002-10-15 | — | — | US | claimed |
| EP-1240130-A1 | METHOD FOR OXIDATION OF XYLENE DERIVATIVES | GENERAL ELECTRIC COMPANY (US) | 2002-09-18 | — | — | EP | claimed |
| EP-1235781-A1 | METHOD FOR OXIDATION OF XYLENE DERIVATIVES | GENERAL ELECTRIC COMPANY (US) | 2002-09-04 | — | — | EP | claimed |
| EP-1235782-A1 | METHOD FOR OXIDATION OF XYLENE DERIVATIVES | GENERAL ELECTRIC COMPANY (US) | 2002-09-04 | — | — | EP | claimed |
| US-6399790-B1 | USING METAL CATALYST | GENERAL ELECTRIC COMPANY | 2002-06-04 | — | — | US | claimed |
| WO-2001038282-A1 | METHOD FOR OXIDATION OF XYLENE DERIVATIVES | GENERAL ELECTRIC COMPANY (US) | 2001-05-31 | — | — | WO | claimed |
| WO-2001038281-A1 | METHOD FOR OXIDATION OF XYLENE DERIVATIVES | GENERAL ELECTRIC COMPANY (US) | 2001-05-31 | — | — | WO | claimed |
| WO-2001038280-A1 | METHOD FOR OXIDATION OF XYLENE DERIVATIVES | GENERAL ELECTRIC COMPANY (US) | 2001-05-31 | — | — | WO | claimed |
| US-12447151-B2 | Alkyne derivative, preparation method for same, and uses thereof | HIS PHARMACEUTICAL CO., LTD. (CN) | 2025-10-21 | — | — | US | disclosed |
| US-12378254-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2025-08-05 | — | — | US | disclosed |
| US-4252659-A | Process for the production of overbased manganese salts of organic acids | TENNECO CHEMICALS, INC. (US) | 1981-02-24 | — | — | US | disclosed |
| US-4179385-A | CARBON DIOXIDE, SOLVENT SYSTEM CONTAINING WATER | TENNECO CHEMICALS, INC. (US) | 1979-12-18 | — | — | US | disclosed |
| US-RE28972-E | SEDATIVES, ANTICONVULSANTS | BOEHRINGER INGELHEIM GMBH (DT) | 1976-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12378254-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | HCRTR2, HCRTR1, OXTR | FABP3 3575/4885FABP4 3536/4885ALDH1A1 3132/4885 |
| US-12447151-B2 | Alkyne derivative, preparation method for same, and uses thereof | PIK3CD, PIK3R5, PIK3CA | FABP3 2306/4885FABP4 3406/4885ALDH1A1 1231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.